You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed/Refractory Multiple Myeloma (R/R MM)

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma, Non-Hodgkin Lymphoma, B-Cell Lymphoma Trial in Korea, Republic of, United States (Tiragolumab,

Active, not recruiting
  • Multiple Myeloma
  • +2 more
  • Denver, Colorado
  • +12 more
Jan 19, 2023

Multiple Myeloma Trial in United States (BION-1301)

Terminated
Has Results
  • Multiple Myeloma
  • BION-1301
  • West Hollywood, California
  • +6 more
Mar 8, 2021

Relapsed/Refractory Multiple Myeloma Trial in Australia, United States (ISB 1442 SC injection escalating doses, ISB 1442 SC

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • ISB 1442 SC injection escalating doses
  • ISB 1442 SC injection at RP2D
  • New York, New York
  • +5 more
Jun 17, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Atlanta (Tocilizumab, Venetoclax)

Recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Jan 24, 2023

Medicine Called Elranatamab in People With Relapsed Refractory

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Jun 30, 2023

Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

Recruiting
  • Advanced Solid Tumors
  • +2 more
  • GIC-102 (Allogeneic NK cells)
  • Gyeonggi-do, Korea, Republic of
  • +3 more
May 18, 2023

Relapsed or Refractory Multiple Myeloma Trial in Shijiazhuang (BCMA CAR-T, Fludarabine, Cyclophosphamide)

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • BCMA CAR-T
  • +2 more
  • Shijiazhuang, Hebei, China
    the Second Hospital of HeBei Medical University (HBMU)
Nov 11, 2020

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Multiple Myeloma, Lymphoma, Non-Hodgkin's Trial in United States (CFT7455, Dexamethasone Oral)

Recruiting
  • Multiple Myeloma
  • Lymphoma, Non-Hodgkin's
  • Phoenix, Arizona
  • +12 more
Dec 12, 2022

Refractory or Relapsed Multiple Myeloma Trial (LCAR-B38M CAR-T cell injection)

Unknown status
  • Refractory or Relapsed Multiple Myeloma
  • LCAR-B38M CAR-T cell injection
  • (no location specified)
Aug 31, 2021

Multiple Myeloma Trial in Charlotte (Elotuzumab)

Active, not recruiting
Has Results
  • Multiple Myeloma
  • Charlotte, North Carolina
    Levine Cancer Institute
Jan 24, 2023

Multiple Myeloma Trial in Wuhan (Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells)

Recruiting
  • Multiple Myeloma
  • Fludarabine + Cyclophosphamide + BCMA-GPRC5D CAR-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Aug 11, 2023

Multiple Myeloma Trial in Athens (Cevostamab, XmAb24306, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Athens, Greece
  • +1 more
Jan 2, 2023

Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)

Not yet recruiting
  • Relapsed and/or Refractory Multiple Myeloma
  • Köln, Germany
    Local Institution - 0017
Dec 4, 2023

Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in Miami (Iberdomide, Carfilzomib, Daratumumab)

Not yet recruiting
  • Refractory Multiple Myeloma
  • Relapsed Multiple Myeloma
  • Miami, Florida
    University of Miami
May 31, 2023

Relapsed Multiple Myeloma, Refractory Multiple Myeloma Trial in United States (REGN5459)

Active, not recruiting
  • Relapsed Multiple Myeloma
  • Refractory Multiple Myeloma
  • Indianapolis, Indiana
  • +6 more
Aug 16, 2022

Multiple Myeloma Trial in Nashville (Cevostamab, Tocilizumab)

Recruiting
  • Multiple Myeloma
  • Nashville, Tennessee
    Tennessee Onc., PLLC - SCRI
Sep 8, 2022

Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Los Angeles (drug, other, biological)

Active, not recruiting
  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Aug 5, 2022

Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Suzhou, Jiangsu, China
    First Affiliated Hospital, Soochow University
Jul 31, 2023

Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Plasma Cell Leukemia
  • CAR-T (CAR-GPRC5D)
  • Wuhan, Hu Bei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
May 17, 2022

Multiple Myeloma Trial (AZD0305)

Not yet recruiting
  • Multiple Myeloma
  • (no location specified)
Oct 24, 2023

Relapsed/Refractory Multiple Myeloma Trial in United States (Belantamab mafodotin)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Belantamab mafodotin
  • Clayton, North Carolina
  • +4 more
May 16, 2023

Multiple Myeloma Trial (REGN5458)

Available
  • Multiple Myeloma
  • (no location specified)
Dec 9, 2021

Multiple Myeloma Trial (CM313 injection)

Not yet recruiting
  • Multiple Myeloma
  • CM313 injection
  • (no location specified)
Nov 6, 2023

Recurrent Multiple Myeloma, Refractory Multiple Myeloma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Recurrent Multiple Myeloma
  • Refractory Multiple Myeloma
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 1, 2023